Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease.

Kano O, Ikeda K, Iwasaki Y, Jiang H.

Neurology. 2013 Sep 24;81(13):1181-2. doi: 10.1212/01.wnl.0000435455.95141.16.

PMID:
24062344
2.

Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease.

Yu X, Du T, Song N, He Q, Shen Y, Jiang H, Xie J.

Neurology. 2013 Jan 29;80(5):492-5. doi: 10.1212/WNL.0b013e31827f0ebb. Epub 2013 Jan 9.

3.

Author response.

Jiang H.

Neurology. 2013 Sep 24;81(13):1182. No abstract available.

PMID:
24191353
4.

Bid signal pathway components are identified in the temporal cortex with Parkinson disease.

Jiang H, He P, Adler CH, Shill H, Beach TG, Li R, Shen Y.

Neurology. 2012 Oct 23;79(17):1767-73. doi: 10.1212/WNL.0b013e3182703f76. Epub 2012 Sep 26.

5.

Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies.

Tam CW, Burton EJ, McKeith IG, Burn DJ, O'Brien JT.

Neurology. 2005 Mar 8;64(5):861-5.

PMID:
15753423
6.
7.
8.
9.

Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.

Naylor JC, Kilts JD, Hulette CM, Steffens DC, Blazer DG, Ervin JF, Strauss JL, Allen TB, Massing MW, Payne VM, Youssef NA, Shampine LJ, Marx CE.

Biochim Biophys Acta. 2010 Aug;1801(8):951-9. doi: 10.1016/j.bbalip.2010.05.006. Epub 2010 May 19.

10.

Increased levels of magnetic iron compounds in Alzheimer's disease.

Pankhurst Q, Hautot D, Khan N, Dobson J.

J Alzheimers Dis. 2008 Feb;13(1):49-52.

PMID:
18334756
11.

kappa-1 Opioid receptors of the temporal cortex are preserved in Alzheimer's disease.

Mackay KB, Dewar D, McCulloch J.

J Neural Transm Park Dis Dement Sect. 1994;7(1):73-9.

PMID:
8579771
12.

Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment.

Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ.

J Neuropathol Exp Neurol. 2006 Jun;65(6):592-601.

13.
14.

Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms.

Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, Hyman BT, Ingelsson M.

Exp Neurol. 2005 Jul;194(1):91-6.

PMID:
15899246
15.

Cortical somatostatinergic system not affected in Alzheimer's and Parkinson's diseases.

Whitford C, Candy J, Edwardson J, Perry R.

J Neurol Sci. 1988 Aug;86(1):13-8.

PMID:
2902199
16.

Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy.

Kuiper MA, Mulder C, van Kamp GJ, Scheltens P, Wolters EC.

J Neural Transm Park Dis Dement Sect. 1994;7(2):109-14.

PMID:
7710663
17.

Evaluation of visual recognition memory in MCI patients.

Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, Ceccaldi M, Poncet M.

Neurology. 2004 Apr 27;62(8):1317-22.

PMID:
15111668
18.

The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease.

Jagust WJ, Eberling JL, Richardson BC, Reed BR, Baker MG, Nordahl TE, Budinger TF.

Brain Res. 1993 Dec 3;629(2):189-98.

PMID:
8111623
19.

Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment.

Mattila PM, Röyttä M, Lönnberg P, Marjamäki P, Helenius H, Rinne JO.

Acta Neuropathol. 2001 Aug;102(2):160-6.

PMID:
11563631
Items per page

Supplemental Content

Write to the Help Desk